Abstract Body (Do not enter title and authors here): Introduction:
Dipeptidyl amino-peptidase 3 (DPP3) is an aminopeptidase released into the bloodstream following cell death. Studies have demonstrated that in patients experiencing cardiogenic shock (CS), there's an elevation in circulating DPP3 (cDPP3) plasma concentration, which is associated with a heightened risk of mortality. This research investigated the connection between serum DPP3 levels, CS occurrence, and mortality in individuals diagnosed with acute coronary syndromes (ACS).

Methods and Materials:
In this prospective, multicentric study, consecutive patients with acute coronary syndrome diagnosis were enrolled, and their plasma levels of DPP3 were evaluated at both baseline and 12-24 hours post-presentation. The ORBI risk score was used to classify patients with a higher risk of cardiogenic shock.

Results:
Elevated circulating levels of DPP3 were linked to in-hospital cardiogenic shock, even when considering established risk factors such as the ORBI risk score (with a hazard ratio of 2.17 per log-2 increase, 95% confidence interval 0.94–1.97, and a P-value <0.005). Additionally, high DPP3 levels were identified as independent predictors of mortality at both 30 days (with a hazard ratio of 2.26, 95% confidence interval 1.14–3.44, and P < 0.001) and one year (with a hazard ratio of 1.57, 95% confidence interval 1.25–2.11, and P < 0.001) after adjusting for established risk factors.

Conclusion:
Our study concludes that circulating DPP3 is a novel marker for cardiogenic shock (CS) and increases mortality risk among ACS patients. Circulating DPP3 may serve as a predictive tool for CS advancement and informing decisions regarding treatment guidelines.